Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (3299)	8/4/2015 1:11:09 PM
From: Jibacoa	Read Replies (3) \| Respond to of 3722

Yes, OPHT is "intriguing", <g> It is due to report its 2ndQ results tomorrow, and that's always a dangerous time, since its is always important that results and guidance beat the expectations.<g> The stock has also been under some pressure by insiders taking some profits, after exercising their options at lower prices. I have a pretty good profit after my recent purchase, and keep my trailing stop loss not too far, trying to protect it.<g> FOVISTA can be used along with REGN's EYLEA, and NVS is supposed to pay OPHT if the results of the PIII come out good. Many people think NVS will buy OPHT. Fidelity and Novo are among major holders. OPHT also has Zimura, an inhibitor of complement factor C5, for the treatment of dry AMD, so yes, I agree that it is an "intriguing" Co., but just in case, will keep fingers crossed tomorrow<g>